<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Ifitm3
  <sup>-/-</sup>
 </italic> mice were generated using TALENs (transcription activator-like effector nucleases) technology based on a C57BL/6J background mice by Biocytogen (Biocytogen, Beijing) [
 <xref rid="CIT0017" ref-type="bibr">17</xref>] and bred in a pathogen free animal facility at the Chinese Center for Disease Control and Prevention. Seven to ten-week-old female wild type (WT) and congenic 
 <italic>Ifitm3
  <sup>-/-</sup>
 </italic> mice were immunized intraperitoneally with 50 μL of TIV (including A/Michigan/45/2015, A/Hong Kong/4801/2014 and B/Victoria/60/2008 viruses) for northern hemisphere 2017–2018 influenza season (lot#201706009) (1.5 μg of each haemagglutinin [HA]) from SINOVAC BIOTECH (SINOVAC, Beijing) followed by a second dose after 14 days.
</p>
